Tangible Shareholders Equity: The value shareholders equity less intangible assets.
Altamira Therapeutics Ltd. (CYTOF) had Tangible Shareholders Equity of $-1.58M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-2.96M |
|
-- |
|
-- |
|
$4.44M |
|
$-4.44M |
|
$1.48M |
|
$-2.96M |
|
$-2.96M |
|
$-2.96M |
|
$-2.96M |
|
$-2.96M |
|
$-2.96M |
|
$-4.44M |
|
$-4.28M |
|
5.37M |
|
5.37M |
|
$-0.55 |
|
$-0.55 |
|
| Balance Sheet Financials | |
$0.26M |
|
$0.09M |
|
$7.68M |
|
$7.94M |
|
$4.42M |
|
-- |
|
$0.47M |
|
$4.89M |
|
$3.05M |
|
|
Tangible Shareholders Equity |
$-1.58M |
$3.05M |
|
5.71M |
|
| Cash Flow Statement Financials | |
$-2.00M |
|
$0.03M |
|
$0.96M |
|
$1.00M |
|
$0.00M |
|
$-1.00M |
|
$0.42M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.06 |
|
-- |
|
-- |
|
-- |
|
0.38 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-1.97M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-97.23% |
|
187.72% |
|
-37.33% |
|
-97.23% |
|
$0.53 |
|
$-0.37 |
|
$-0.37 |
|